Prognostic significance of VEGF-C expression in correlation with COX-2, lymphatic microvessel density, and clinicopathologic characteristics in human non-small cell lung cancer

Acta Biochimica et Biophysica Sinica

Volumn 41, Issue 3, 2009, Pages 217-222

  Guo, Xufeng ^a   Chen, Yongbing ^a   Xu, Zhonghua ^a   Xu, Zhonghen ^a   Qian, Yongyue ^a   Yu, Xueyan ^b  

^a THE SECOND AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Cyclooxygenase 2; Lymphangiogenesis; Lymphatic microvessel density; Vessel endothelial growth factor C

Indexed keywords

CYCLOOXYGENASE 2; PTGS2 PROTEIN, HUMAN; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 3;

ARTICLE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; LYMPH VESSEL; LYMPHANGIOGENESIS; MALE; METABOLISM; MICROVASCULATURE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SURVIVAL;

CARCINOMA, NON-SMALL-CELL LUNG; CYCLOOXYGENASE 2; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; LYMPHANGIOGENESIS; LYMPHATIC METASTASIS; LYMPHATIC VESSELS; MALE; MICROVESSELS; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 65249113902     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmp004     Document Type: Article

References (25)

1. Renyi-Vamos F, Tovari J, Fillinger J, Timar J, Paku S, Kenessey I and Gyula Ostoros, et al. Lymphangiogenesis con-elates with lymph node metastasis, prognosis, and angiogenic phenotype in human non-small cell lung cancer. Clin Cancer Res 2005, 11: 7344-7353.
2. Al-Rawi MA, Mansel RE and Jiang WG. Lymphangiogenesis and its role in cancer. Histol Histopathol 2005, 20: 283-298.
3. Inoue A, Moriya H, Katada N, Tanabe S, Kobayashi N, Watanabe M and Okayasu I, et al. Intratumoral lymphangiogenesis of esophageal squamous cell carcinoma and relationship with regulatory factors and prognosis. Pathol Int 2008, 58: 611-619.
4. Jackson DG. New molecular markers for the study of tumor lymphangiogenesis. Anticancer Res 2001, 21: 4279-4283.
5. Da MX, Wu Z and Tian HW. Tumor lymphangiogenesis and lymphan-giogenic growth factors. Arch Med Res 2008, 39: 365-372.
6. Cao Y and Zhong W. Tumor-derived lymphangiogenic factors and lymphatic metastasis. Biomed Pharmacother 2007, 61: 534-539.
7. Su JL, Chen PS, Chien MH, Chen PB, Chen YH, Lai CC and Hung MC, et al. Further evidence for expression and function of the VEGF-C/VEGFR-3 axis in cancer cells. Cancer Cell 2008, 1.3: 557-560.
8. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB and Lipsky PE. Cyclooxygenase in biology and disease. FASEB J 1998, 12: 1063-1073.
9. Williams CS, Mann M and DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999, 18: 7908-7916.
10. Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB and De Marzo AM. Cyclooxygenases in cancer: progress and perspective. Cancer Lett 2004, 215: 1-20.
11. Pan MR, Hou MF, Chang HC and Hung WC. Cyclooxygenase-2 up-regulates CCR7 via EP2/EP4 receptor signaling pathways to enhance lymphatic invasion of breast cancer cells. J Biol Chem 2008, 283: 11155-11163.
12. Jüttner S, Wissmann C, Jöns T, Vieth M, Hertel J, Gretschel S and Schlag PM, et al. Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol 2006, 24: 228-240.
13. Miyahara M, Tanuma J, Sugihara K and Semba I. Tumor lymphangiogenesis correlates with lymph node metastasis and clinicopathologic parameters in oral squamous cell carcinoma. Cancer 2007, 110: 1287-1294.
14. Duff SE, Jeziorska M, Kumar S, Haboubi N, Sherlock D, O'Dwyer ST and Jayson GC. Lymphatic vessel density, microvessel density and lymphangiogenic growth factor expression in colorectal cancer. Colorectal Dis 2007, 9: 793-800.
15. Schoppmann SF, Fenzl A, Nagy K, linger S, Bayer G, Geleff S and Gnant M, et al. VEGF-C expressing tumor-associated macrophages in lymph node positive breast cancer: impact on lymphangiogenesis and survival. Surgery 2006, 139: 839-846.
16. Patel S and Chiplunkar S. Role of cyclooxygenase-2 in tumor progression and immune regulation in lung cancer. Indian J Biochem Biophys 2007, 44: 419-428.
17. Joachims Z, Feiumesser R, Purim O, Halpern M, Brenner B, Fenig E and Roizman P, et al. Cyclooxygenase-2 expression in primary and metastatic Merkel cell carcinoma. Appl Immuuohistochem Mol Morphol 2008, 16: 442-446.
18. Hammam OA, Aziz AA, Roshdy MS and Abdel Hadi AM. Possible role of cyclooxygenase-2 in schistosomal and non-schistosomal-associated bladder cancer. Medscape J Med 2008, 10: 60.
19. Gately S. The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev 2000, 19: 19-27.
20. Saukkonen K, Rintahaka J, Sivula A, Buskens CJ, Van Rees BP, Rio MC and Haglund C, et al. Cyclooxygenase-2 and gastric carcinogenesis. APMIS 2003, 111: 915-925.
21. Kolev Y, Uetake H, Iida S, Ishikawa T, Kawano T and Sugihara K. Prognostic significance of VEGF expression in correlation with COX-2, microvessel density, and clinicopathological characteristics in human gastric carcinoma. Ann Surg Oncol 2007, 14: 2738-2747.
22. Hammes LS, Tekmal RR, Naud P, Edelweiss MI, Kirma N, Valeute PT and Syrjänen K.T, et al. Up-regulation of VEGF, c-fms and COX-2 expression correlates with severity of cervical cancer precursor (CIN) lesions and invasive disease. Gynecol Oncol 2008, 110: 445-451.
23. Alitalo K, Tammela T and Petrova TV. Lymphangiogenesis in development and human disease. Nature 2005, 14: 946-953.
24. Wissmann C and Detmar M. Pathways targeting tumor lymphangiogenesis. Clin Cancer Res 2006, 23: 6865-6868.
25. Achen MG, McColl BK and Stacker SA. Focus on lymphangiogenesis in tumor metastasis. Cancer Cell 2005, 2: 121-127.